Flexipharm Austrading is a young specialty pharmaceutical company focused on supplying the UK NHS with Better. Critical Care Medicines.
This website is intended for Healthcare Professionals.
If you are a patient seeking information you should consult your doctor or nurse. If you are involved in the purchase, supply or prescribing of medicines and / or pharmaceuticals please read on to learn more about Flexipharm Austrading and what we can offer.
We focus on injectable presentations of “gold standard drugs” which are improvements on the current products available to NHS hospitals.
We pride ourselves on understanding the conditions where our medicines are used and building meaningful dialogue with the NHS staff involved in using our medicines. We are responsive to inquiries from the NHS and will always provide prompt, accurate and fact-based data when requested.
Flexipharm Austrading was set up in 2018 by Michael Clark, an experienced specialty pharmaceutical company founder and board director. It is a privately owned limited UK company.
Our vision is to be known by NHS hospitals and specialist procurement and quality pharmacists as a highly respected, reliable and trusted supplier of generic injectable medicines for critically ill patients.
We are singularly focused on providing novel presentations of established (or “gold standard”) molecules embedded in hospital use where there are one or more of the following challenges;
Led by our founder, Michael Clark, we are agile and responsive and we have no barriers to quick decision making. Our exclusive distribution agreement with Phebra will see us launch additional innovative injectable critical care medicines in 2021.
1. We only supply better presentations:
2. We offer savings over the more expensive options:
3. We are a reliable and high-quality manufacturer:
Flexipharm Austrading is principally a commercial organisation which seeks to acquire exclusive distribution rights to novel or better presentations of injectable critical care medicines which we then supply to NHS and private hospitals.
Flexipharm Austrading only supplies medicines which demonstrate clear advantages and improvements over existing products.
The company holds a Wholesaler Dealers Authorisation, a Manufacturers “Specials” License and a Manufacturers/Importers Authorisation. These allow Flexipharm Austrading to file and hold Marketing Authorisations as well as to import, certify, and distribute human prescription medicines for sale in the UK.
Flexipharm Austrading's day-to-day operations are supported by specialist providers of quality assurance, pharmacovigilance and supply chain services and the company follows all applicable guidelines including Good Manufacturing Practice, Good Distribution Practice and Good Pharmacovigilance Services.
The company has an exclusive license and distribution agreement with Phebra Pty Ltd, an Australian company that develops, manufactures and supplies high quality and innovative pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market, details can be found at www.phebra.com
Flexipharm Austrading is responsible for importation, release for sale and supply of selected Phebra products in the UK.
Flexipharm Austrading has an established partnership and exclusive distribution agreement with Phebra Pty Ltd, an Australian company that develops, manufactures and supplies high quality and innovative pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market, www.phebra.com.
The first product launched from the partnership was Arsenic Trioxide Phebra, a novel vial presentation of arsenic trioxide (concentrate for solution for infusion) indicated for the treatment of low-intermediate risk Acute Promyelocytic Leukaemia (APML).
Arsenic Trioxide Phebra received UK regulatory approval in May 2019 and is available from Mawdsleys, our exclusive wholesaler partner for Arsenic Trioxide Phebra. Flexipharm Austrading has implemented a life-cycle plan, taking needs from specialist haemato-oncology pharmacists to improve the product presentation with a best-in-class in-use shelf life and a novel, first to market protective sleeve and base cup. These measures enhance utility and safety of the product for NHS specialist pharmacists. Read the press release here.
The second product is Methylthioninium Chloride, a novel vial presentation this important medicine, Flexipharm Austrading’s Methylthioninium Chloride product is also available from Mawdsleys. Flexipharm Austrading Methylthioninium Chloride vial presentation helps protect NHS staff by removing the risk of sharps injuries from opening ampoules. Read the press release here.
Flexipharm Austrading is planning to launch additional products from the Phebra portfolio during 2021.
Flexipharm Austrading is focused on offering tangible value to the NHS. All our products meet three parameters; better, cheaper and fairer
Our products are all presented in vials; most UK injectable essential medicines are supplied as ampoules. Vials have the significant advantage that there is no risk of a sharps injury from the top of an opened ampoule or a glass fragment when drawing up the drug from a vial.
We are also focused on introducing new strengths of medicines which remove the need for dilution before administration; a process which can contribute to medication errors.
We will launch our products with an NHS or List price lower than the existing product to enable the NHS to save money.
As our products are vials, we save the NHS money by removing the need to use filter straws/filter needles to draw the drug from the vial.
Flexipharm Austrading guarantees not to increase the prices for our products if we are in a “sole supply” situation.
Our planned product launches are for medicines where there is currently one manufacturer supplying the UK, so if that product is not available the NHS will have a second licensed equivalent product for patients.
Flexipharm Austrading will apply to have our products included on NHS Framework Agreements so NHS hospitals can easily access and order our products. We also commit to maintain stores in the UK equivalent to at least 4 months of NHS demand.